Skip to main content
. 2021 Mar 31;12:629902. doi: 10.3389/fimmu.2021.629902

Table 1.

Baseline clinical characteristics of SNV patients with stroke and those without stroke.

Total, n=2644 Patients with stroke, n=159 Patients without stroke, n=2485 p-value
Age at diagnosis (years) 56.65 ± 16.84 66.50 ± 13.34 56.02 ± 16.85 <0.001
 ≤54 1052 (39.8) 28 (17.6) 1024 (41.2) <0.001
 55-74 1225 (46.3) 84 (52.8) 1141 (45.9)
 ≥75 367 (13.9) 47 (29.6) 320 (12.9)
Sex, n (%) 0.885
 Male 1191 (45.1) 73 (45.9) 1118 (45.0)
 Female 1453 (54.9) 86 (54.1) 1367 (55.0)
Diagnosis [ICD-10 code], n (%) <0.001
 MPA (M31.7) 904 (34.2) 79 (49.7) 825 (33.2)
 GPA (M31.3) 606 (22.9) 31 (19.5) 575 (23.1)
 EGPA (M30.1) 593 (22.4) 32 (20.1) 561 (22.6)
 PAN (M30.0) 541 (20.5) 17 (10.7) 524 (21.1)
Geographic Area, n (%) 0.219
 Seoul 1197 (45.3) 64 (40.3) 1133 (45.6)
 Outside Seoul 1447 (54.7) 95 (59.7) 1352 (54.4)
Comorbidities [ICD-10 code]
Hypertension [I10-15] <0.001
 No 1477 (55.9) 60 (37.7) 1417 (57.0)
 Yes 1167 (44.1) 99 (62.3) 1068 (43.0)
Diabetes mellitus [E10-14] <0.001
 No 1813 (68.6) 87 (54.7) 1726 (69.5)
 Yes 831 (31.4) 72 (45.3) 759 (30.5)
Atrial fibrillation/flutter [I48] 0.299
 No 2576 (97.4) 153 (96.2) 2423 (97.5)
 Yes 68 (2.6) 6 (3.8) 62 (2.5)
Dyslipidemia [E78] 0.005
 No 1409 (53.3) 67 (42.1) 1342 (54.0)
 Yes 1235 (46.7) 92 (57.9) 1143 (46.0)
Medication usage, n (%)
Immunosuppressive agents
 Glucocorticoid usage ≥ 1
 year
1225 (46.3) 31 (19.5) 1194 (48.1) <0.001
 Cyclophosphamide 1124 (42.5) 62 (39.0) 1062 (42.7) 0.399
 Rituximab 252 (9.5) 8 (5.0) 244 (9.8) 0.064
 Azathioprine/mizoribine 991 (37.5) 29 (18.2) 962 (38.7) <0.001
 Methotrexate 431 (16.3) 8 (5.0) 423 (17.0) <0.001
Antiplatelet agents
 Aspirin 608 (23.0) 32 (20.1) 576 (23.2) 0.430
 Clopidogrel 232 (8.8) 10 (6.3) 222 (8.9) 0.318
Statins 996 (37.7) 45 (28.3) 951 (38.3) 0.015

Values are expressed as mean (standard deviation) or number (percentages).

SNV, systemic necrotizing vasculitis; ICD, International classification of diseases; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa.